Arcus Biosciences, Inc. (RCUS) stock
Close on Nov 11, 2026Market cap $2.39BP/E –Yield –
Arcus Biosciences, Inc. saw revenue fall 58.3% to $100.00M over the twelve months to Sep 30, 2026. Free cash flow was -$466.00M. At the latest close the market valued the company at $2.39B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $2.39B
- P/E ratio
- –
- Price to sales
- 23.94
- Price to book
- 6.69
- Dividend yield
- –
- Free cash flow yield
- -19.47%
Fundamentals
- Revenue
- $100.00M
- Net income
- -$453.00M
- EPS, diluted
- -$3.63
- Free cash flow
- -$466.00M
- Book value per share
- $2.81
- Diluted shares
- 127M
Trading
- Next earnings
- Feb 24, 2027 (estimated, during market hours)
- Previous close
- $18.67
- Open
- $19.00
- Day's range
- $18.54 – $19.00
- Volume
- 914,963
- Average volume (20 days)
- 2,671,311
- Index membership
- S&P SmallCap 600 (since May 2022), Russell 2000, Russell 3000
- Beta (5 years)
- 1.43
- 52-week range
- $17.43 – $31.73
- RSI (14 days)
- 40.7
- Volatility (1 year)
- 62.4%
- Relative volume
- 0.56×
- WACC
- 12.0%
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | RCUS | S&P 500 | Difference | RCUS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.0% | -2.4% | −20.6 pts | ||
| 3 months | -34.6% | -1.2% | −33.4 pts | ||
| Year to date | -21.1% | +12.3% | −33.4 pts | ||
| 1 year | -7.3% | +12.4% | −19.8 pts | ||
| 3 years | +38.8% | +78.8% | −40.0 pts | +11.6% | +21.4% |
| 5 years | -49.8% | +75.2% | −125.0 pts | -12.9% | +11.9% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Arcus Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Arcus Biosciences
Pharmaceutical Preparations
Arcus is a clinical-stage biopharmaceutical company that develops small-molecule therapies and antibodies for patients with cancer and autoimmune or inflammatory diseases. Its primary oncology pipeline includes casdatifan, an oral HIF-2α inhibitor for kidney cancer; quemliclustat, a CD73 enzyme inhibitor for pancreatic cancer; domvanalimab, an anti-TIGIT antibody for lung cancer; and zimberelimab, an anti-PD-1 antibody. The company also pursues preclinical research targeting inflammatory conditions such as chronic urticaria and atopic dermatitis. Its end users are individuals with these oncologic and inflammatory disorders.
Company profile, executives and historyArcus Biosciences stock: common questions
What is Arcus Biosciences's stock price?
RCUS closed at $18.80 on Nov 11, 2026, up 0.70% on the day. Over the past 52 weeks it traded between $17.43 and $31.73.
What is Arcus Biosciences's market cap?
Arcus Biosciences was worth $2.39B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is RCUS's P/E ratio?
Arcus Biosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.63), so it has no meaningful P/E ratio.
How much revenue does Arcus Biosciences make?
Arcus Biosciences reported revenue of $100.00M for the twelve months to Sep 30, 2026, down 58.3% from a year earlier.
Does Arcus Biosciences pay a dividend?
No. Arcus Biosciences has not paid a cash dividend over the last twelve months.
When does Arcus Biosciences report earnings next?
Arcus Biosciences is expected to report Q4 FY2026 results on Feb 24, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has RCUS stock performed over the past year?
Including dividends, RCUS returned -7.3% over the past year, against +12.4% for the S&P 500.
How many RCUS shares are sold short?
13M shares were sold short at the latest FINRA report, 15.16% of the float, or 3.6 days of average trading volume.
Who are Arcus Biosciences's competitors?
Companies most similar to Arcus Biosciences by business, industry and size include VSTM, XNCR, NUVB, KURA, KYMR.
See a number that looks wrong?